Armistice Capital LLC Has $19.46 Million Stake in Bicycle Therapeutics PLC Sponsored ADR $BCYC

Armistice Capital LLC grew its stake in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) by 4.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,800,000 shares of the company’s stock after purchasing an additional 128,000 shares during the period. Armistice Capital LLC owned about 4.04% of Bicycle Therapeutics worth $19,460,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in BCYC. Long Focus Capital Management LLC boosted its position in Bicycle Therapeutics by 138.2% in the first quarter. Long Focus Capital Management LLC now owns 1,293,753 shares of the company’s stock valued at $10,984,000 after buying an additional 750,661 shares in the last quarter. Acadian Asset Management LLC lifted its stake in shares of Bicycle Therapeutics by 454.1% in the 2nd quarter. Acadian Asset Management LLC now owns 698,501 shares of the company’s stock valued at $4,840,000 after acquiring an additional 572,439 shares during the last quarter. Tybourne Capital Management HK Ltd. boosted its holdings in shares of Bicycle Therapeutics by 72.4% during the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 993,743 shares of the company’s stock valued at $6,907,000 after acquiring an additional 417,400 shares in the last quarter. Woodline Partners LP bought a new stake in Bicycle Therapeutics during the 1st quarter worth $3,088,000. Finally, Millennium Management LLC increased its holdings in Bicycle Therapeutics by 156.5% in the 1st quarter. Millennium Management LLC now owns 453,428 shares of the company’s stock worth $3,850,000 after purchasing an additional 276,671 shares in the last quarter. 86.15% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on BCYC. Royal Bank Of Canada restated a “sector perform” rating and set a $11.00 price target (down from $27.00) on shares of Bicycle Therapeutics in a report on Friday, October 31st. Citigroup reissued an “outperform” rating on shares of Bicycle Therapeutics in a report on Friday, October 31st. Citizens Jmp raised their price target on shares of Bicycle Therapeutics from $10.00 to $12.00 and gave the company a “market outperform” rating in a research note on Friday, October 31st. JMP Securities set a $12.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Finally, Truist Financial assumed coverage on Bicycle Therapeutics in a report on Monday, November 24th. They issued a “hold” rating and a $10.00 price objective for the company. Seven investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $19.73.

Bicycle Therapeutics Trading Down 1.2%

Shares of BCYC opened at $7.43 on Friday. The firm’s fifty day simple moving average is $7.42 and its two-hundred day simple moving average is $7.59. Bicycle Therapeutics PLC Sponsored ADR has a 12 month low of $6.03 and a 12 month high of $21.14. The stock has a market capitalization of $515.42 million, a P/E ratio of -2.05 and a beta of 1.47.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings data on Thursday, October 30th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.24. Bicycle Therapeutics had a negative return on equity of 36.05% and a negative net margin of 884.51%.The company had revenue of $11.73 million for the quarter, compared to the consensus estimate of $8.25 million. As a group, research analysts predict that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 EPS for the current fiscal year.

Insider Transactions at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,231 shares of the stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $8.41, for a total transaction of $27,172.71. Following the transaction, the chief executive officer directly owned 475,310 shares in the company, valued at approximately $3,997,357.10. This represents a 0.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 8,527 shares of company stock valued at $71,738 over the last quarter. 22.90% of the stock is currently owned by insiders.

Bicycle Therapeutics Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.